lapatinib has been researched along with Carcinoma, Ovarian Epithelial in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bindhya, S; Ganesan, TS; Joshua, T; Krishnapriya, S; Manasa, P; Murhekar, K; Nagare, RP; Shabna, A; Sidhanth, C; Sneha, S | 1 |
| Armstrong, DK; Carolla, RL; Fischer, EG; Garcia, AA; Godwin, AK; Lankes, HA; Leslie, KK; Liepman, MK; Mannel, RS; Sill, MW; Spirtos, NM | 1 |
| Blanc-Fournier, C; Bourgeois, H; Briand, M; Clarisse, B; Fabbro, M; Joly, F; Krieger, S; Leconte, A; Lheureux, S; Lortholary, A; Pautier, P; Petit, T; Plantade, A; Richard, N; Selle, F; Vilquin, P; Weber, B | 1 |
2 trial(s) available for lapatinib and Carcinoma, Ovarian Epithelial
| Article | Year |
|---|---|
A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Disease-Free Survival; ErbB Receptors; Female; Humans; Ki-67 Antigen; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Polymorphism, Genetic; Quinazolines | 2012 |
Expected benefits of topotecan combined with lapatinib in recurrent ovarian cancer according to biological profile: a phase 2 trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Female; Humans; Lapatinib; Metabolome; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Quinazolines; Recurrence; Risk Assessment; Topotecan; Treatment Outcome; Young Adult | 2012 |
1 other study(ies) available for lapatinib and Carcinoma, Ovarian Epithelial
| Article | Year |
|---|---|
LASP-1 interacts with ErbB2 in ovarian cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Adult; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cohort Studies; Cytoskeletal Proteins; Female; HEK293 Cells; Humans; Lapatinib; LIM Domain Proteins; Middle Aged; Ovarian Neoplasms; Phosphorylation; Plasmids; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Transfection | 2022 |